Login

RAPT Therapeutics, Inc. 8-K SEC Filings

Filed On Filing
03 Mar 2026 8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +4 more

SECTION 1.1 REGISTERED OFFICE. The registered office shall be established and maintained at the office of Corporation Service Company, in the City of Wilmington, in the county of New Castle, in the State of Delaware, and said corporation...

20 Jan 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

a public limited company organized under the laws of England and Wales

14 Jan 2026 8-K: Regulation FD Disclosure

Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of ozureprubart (RPT9...

28 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

On November 24, 2025, RAPT Therapeutics, Inc. (the “Company”) and Dr. William Ho, Chief Medical Officer, mutually agreed that Dr. Ho will leave the Company on December 31, 2025 (the “Separation Date”).

06 Nov 2025 8-K: Results of Operations and Financial Condition

Initiated prestIgE Phase 2b trial of ozureprubart in food allergy

23 Oct 2025 8-K: Other Events

As Representatives of theseveral Underwriters listedin Schedule 1 hereto

20 Oct 2025 8-K: Regulation FD Disclosure; Other Events

THE SCIENCE TO OVERCOME INFLAMMATION OCTOBER 20, 2025 Phase 2 Topline Results of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

07 Aug 2025 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif. – August 7, 2025 – RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel the...

08 Jul 2025 8-K: Regulation FD Disclosure

THE SCIENCE TO OVERCOME INFLAMMATION CORPORATE PRESENTATION JULY 2025 Exhibit 99.1

23 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation

On June 21, 2025, the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) increased the size of the Board from five to seven directors and, upon the recommendation of its Nominating and Corporate Governance Commit...

17 Jun 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

RAPT Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that:

09 Jun 2025 8-K: Regulation FD Disclosure

THE SCIENCE TO OVERCOME INFLAMMATION CORPORATE PRESENTATION JUNE 2025 Exhibit 99.1

29 May 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

On May 29, 2025, RAPT Therapeutics, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved (i) the RAPT Therapeutics, Inc. 2025 Equity Incentiv...

28 May 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On May 21, 2025, RAPT Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average closing bid price ...

08 May 2025 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif. – May 8, 2025 – RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therap...

27 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

(b) On March 21, 2025, Dr. Wendye R. Robbins notified the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) that she will not stand for election at the Company’s 2025 annual meeting of stockholders (the “Annual ...

06 Mar 2025 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif. – March 6, 2025 – RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel th...

13 Jan 2025 8-K: Regulation FD Disclosure

Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development...

06 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

On January 3, 2025, William Rieflin resigned from the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”), effective immediately. Mr. Rieflin’s departure from the Board is not the result of any disagreement with t...

23 Dec 2024 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support